Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 25 of 63 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/01/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 01/01/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 02/17/23
End: 02/29/24
Due: 02/28/25
Phase: N/A
Priority: Normal
Start: 12/01/22
End: 06/01/27
Due: 06/01/28
Phase: N/A
Priority: Normal
Start: 05/30/21
End: 10/31/22
Due: 10/31/23
Phase: N/A
Priority: Normal
Start: 09/30/21
End: 08/31/24
Due: 08/31/25
Phase: N/A
Priority: Normal
Start: 07/05/21
End: 04/20/22
Due: 04/20/23
Phase: N/A
Priority: Normal
Start: 05/01/21
End: 05/01/28
Due: 05/01/29
Phase: N/A
Priority: Normal
Start: 03/01/25
End: 12/31/30
Due: 12/31/31
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Phase: N/A
Priority: Normal
Start: 04/15/21
End: 04/15/26
Due: 04/15/27
Phase: N/A
Priority: Normal
Start: 05/09/24
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 12/23/21
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 03/01/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 09/15/23
End: 12/01/30
Due: 12/01/31
Phase: N/A
Priority: Normal
Start: 01/01/22
End: 12/31/26
Due: 12/31/27
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 05/31/27
Due: 05/31/28
Phase: N/A
Priority: Normal
Start: 09/20/22
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 12/01/21
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 10/15/23
End: 07/05/24
Due: 07/05/25
Phase: N/A
Priority: Normal
Start: 10/22/20
End: 03/31/21
Due: 03/31/22
Phase: N/A
Priority: Normal
Start: 11/10/20
End: 03/10/22
Due: 03/10/23
Phase: N/A
Priority: Normal
Start: 03/01/19
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 10/26/23
End: 09/10/27
Due: 09/10/28
Phase: N/A
Priority: Normal
Start: 12/24/18
End: 09/01/30
Due: 09/01/31
Phase: N/A
Priority: Normal
Start: 09/18/21
End: 09/30/24
Due: 09/30/25